Nanoviricides (NNVC) Change in Account Payables (2010 - 2026)
Nanoviricides (NNVC) posted Change in Account Payables of -$24542.0 for Q1 2026, down 187.37% sequentially from $28089.0 in Q4 2025, and up 53.96% YoY from -$15940.5 in Q1 2025.
Nanoviricides (NNVC) Change in Account Payables (2010 - 2026) Analysis & Trends
Nanoviricides has reported Change in Account Payables for 17 years, with the latest figure at -$24542.0 in Q1 2026.
- Quarterly Change in Account Payables rose 53.96% year-over-year to -$24542.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $72620.0 (down 78.19% YoY) and the FY2025 annual result came in at $82824.0, down 62.22% from the prior year.
- Change in Account Payables slipped to -$24542.0 in Q1 2026 per NNVC's latest filing, from $28089.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $259887.0 in Q2 2022 and troughed at -$290891.0 in Q1 2024.
- A 5-year average of $26573.9 and a median of -$10447.0 in 2023 frame the typical range for Change in Account Payables.
- The widest YoY moves for Change in Account Payables: up 2392.51% in 2024, down 157.16% in 2024.
- Over 5 years, Change in Account Payables stood at -$59695.0 in 2022, then surged by 308.65% to $124554.0 in 2023, then soared by 84.85% to $230233.0 in 2024, then slumped by 87.8% to $28089.0 in 2025, then slumped by 187.37% to -$24542.0 in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered -$24542.0, $28089.0, and $79687.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Nanoviricides | 28.74 Mn | 25.53 Mn | - | -24,542.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24,542.00 |
| Mar 31, 2026 | -24,542.00 |
| Dec 31, 2025 | 28,089.00 |
| Dec 31, 2025 | 28,089.00 |
| Sep 30, 2025 | 79,687.00 |
| Sep 30, 2025 | 79,687.00 |
| Jun 30, 2025 | -10,614.00 |
| Jun 30, 2025 | -10,614.00 |
| Mar 31, 2025 | -53,306.00 |
| Mar 31, 2025 | -53,306.00 |
| Dec 31, 2024 | 230,233.00 |
| Dec 31, 2024 | 230,233.00 |
| Sep 30, 2024 | -83,489.00 |
| Sep 30, 2024 | -83,489.00 |
| Jun 30, 2024 | 239,499.00 |
| Jun 30, 2024 | 239,499.00 |
| Mar 31, 2024 | -290,891.00 |
| Mar 31, 2024 | -290,891.00 |
| Dec 31, 2023 | 124,554.00 |
| Dec 31, 2023 | 124,554.00 |